# MOCK SHELL: Table 14-4.01

## Overview of Adverse Events

---

**Protocol:** CDISCPILOT01
**Population:** Safety

---

| | Placebo | Xanomeline Low Dose | Xanomeline High Dose | Total |
|---|---------|---------------------|----------------------|-------|
| | (N=nnn) | (N=nnn) | (N=nnn) | (N=nnn) |
|---|---------|---------------------|----------------------|-------|
| **Number of subjects with at least one:** | | | | |
| Adverse Event | nn (xx.x) | nn (xx.x) | nn (xx.x) | nn (xx.x) |
| Treatment-Emergent Adverse Event | nn (xx.x) | nn (xx.x) | nn (xx.x) | nn (xx.x) |
| Serious Adverse Event | nn (xx.x) | nn (xx.x) | nn (xx.x) | nn (xx.x) |
| Adverse Event leading to death | nn (xx.x) | nn (xx.x) | nn (xx.x) | nn (xx.x) |
| Adverse Event leading to discontinuation | nn (xx.x) | nn (xx.x) | nn (xx.x) | nn (xx.x) |
| Adverse Event leading to dose interruption | nn (xx.x) | nn (xx.x) | nn (xx.x) | nn (xx.x) |
| | | | | |
| **Total number of:** | | | | |
| Adverse Events | nnn | nnn | nnn | nnn |
| Treatment-Emergent Adverse Events | nnn | nnn | nnn | nnn |
| Serious Adverse Events | nnn | nnn | nnn | nnn |
| Deaths | nnn | nnn | nnn | nnn |

---

**Notes:**
- N = Number of subjects in the Safety population
- n = Number of subjects with the specified event
- (%) = Percentage of subjects with the specified event
- A subject with multiple occurrences of an event is counted only once.
- Treatment-Emergent Adverse Events are defined as events starting on or after the first dose of study drug.

**Program:** tlf-ae-overview.R
**Source:** ADAE, ADSL

---

*Mock Shell Template - For specification purposes only*
